Проблема выбора антикоагулянта для профилактики инсульта у больных с фибрилляцией предсердий

СтатьяМЕД СОВЕТ. 2014; № 12: 58–64. DOI:10.21518/2079-701X-2014-12-58-64

Долгова Е.^[1]

Соколов И.М.^[1]

Шварц Ю.Г.^[1]

^[1]Саратовский государственный медицинский университет им. В. И. Разумовского

В обзоре представлены данные литературы о проблеме тромбоэмболических осложнений при неклапанной фибрилляции предсердий, об особенностях антикоагулянтной терапии при данной патологии и трудностях, возникающих при выборе препарата для профилактики инсульта.

фибрилляция предсердий

тромбоэмболи-ческие осложнения

антикоагулянтная терапия

инсульт

варфарин

апиксабан

ривароксабан

дабигатран

Антикоагулянты

Безопасность

Боли

Больные

Варфарин

Время

Геморрагии

Дабигатран

Ишемический инсульт

Литература

Патология

Предсердие

Причинная связь

Ривароксабан

Риск

Смертность

Тромбин

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest, 2010, 137: 263-272.

Stewart S, Murphy N, Walker A et al. Cost of an emerging epidemic. an economic analysis of atrial fibrillation in the UK. Heart, 2004, 90: 286-292.

Patel MR for ROCKET AF Executive Steering Committee. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation, 2010, 122 (Suppl. 21): 2217.

Wadelius M, Chen LY, Downes K et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics, 2005, 5 (4): 262-70.

ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation. Eur Heart J 2010, 31: 2369-2429.

Feinberg WM, Cornell ES, Nightingale SD et al. Stroke Prevention in Atrial Fibrillation Investigators Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke 1997. 28: 1101-1106.

Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007, 28: 2803-2817.

Friberg J, Buch P, Scharling H, Gadsbphioll N et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003, 14: 666-672.

Levy S, Maarek M, Coumel P et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists Circulation, 1999, 99: 3028-3035.

Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulations and Risk factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285(18): 2370-5.

Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation. the Framingham Heart Study. Circulation 12004-, 110: 1042- 1046.

Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009. 373. 155-166

Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.JAMA 2001, 285: 2864-2870.

Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349: 1019-1026.

Язык текста: Русский

ISSN: 2079-701X